Prior alcohol consumption does not impair HCV treatment

Prior alcohol consumption does not impair HCV treatment
For patients with hepatitis C virus treated with pegylated interferon-alpha and ribavirin, drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.

(HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according to a study published in the October issue of Hepatology.

Marcia Russell, Ph.D., from the Pacific Institute for Research and Evaluation in Berkeley, Calif., and colleagues examined the on treatment outcome in 421 treatment-naive HCV-positive patients, who were members of an integrated health care plan and were treated with P/R. For 259 of the patients, a detailed drinking history was obtained.

The researchers found that, before HCV diagnosis, regular drinking was reported by 93.1 percent of patients. Between HCV diagnosis and treatment, 30.9 percent reported regular drinking, and this dropped to 1.9 percent during treatment and 11.6 percent after the end of treatment. Before starting treatment, 67.9 percent reported heavy drinking patterns, with 63.5 percent drinking more than 100 kg of ethanol, while 29.3 percent reported abstaining less than the requisite six months before initiation of treatment. In spite of these patterns, 80.2 percent of patients with HCV genotype 2 or 3 and 45.1 percent with genotype 1, 4, or 6 had a sustained (SVR). Neither pretreatment drinking patterns nor total alcohol intake was related to SVR rates. Lower SVR rates were seen in moderate, but not heavy, drinkers who abstained for less than six months before treatment.

"These findings suggest that past heavy drinking and recent drinking represent low treatment risk in these patients," the authors write.

One author disclosed to Merck.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Treating hepatitis C infection in prison is good public policy

Sep 27, 2012

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer ...

Coffee drinking improves hepatitis C treatment response

Jun 07, 2011

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) ...

Hypertension ups retinopathy risk with HCV treatment

Aug 02, 2012

(HealthDay) -- For patients with hepatitis C virus (HCV) treated with pegylated interferon alpha (PegIFNα) and ribavirin, retinopathy occurs frequently, especially in those with hypertension, according ...

Recommended for you

France to receive first Ebola patient

2 hours ago

France on Wednesday prepared to receive its first Ebola patient, as the World Bank warned the spiralling epidemic is threatening economic catastrophe in west Africa.

US scientist: Ebola unlikely to become airborne

3 hours ago

It is unlikely that Ebola would mutate to spread through the air, and the best way to make sure it doesn't is to stop the epidemic, a top U.S. government scientist told concerned lawmakers Wednesday.

User comments